Regulatory news dominates the morning session as Cipla faces USFDA observations at its key Pithampur facility. Meanwhile, Cupid’s promoters boost confidence with substantial open-market acquisitions. Here's what's moving.

Cipla

• Regulatory: The company received a Form 483 with seven observations from the USFDA following a follow-up inspection at its Unit IV in Pithampur. This facility contributes 30% of total revenue, raising concerns about potential impacts on US export capabilities. Stock closed at ₹1422.00 in the previous session, down 1.11%.
• Corporate action: NCLT approved the amalgamation of wholly-owned subsidiary Inzpera Healthsciences with Cipla to consolidate operations and reduce compliance costs. No new shares will be issued, and all Inzpera equity shares will be cancelled.

CEAT

• Regulatory: The Competition Commission of India (CCI) cleared CEAT of any wrongdoing in a probe regarding alleged bid-rigging in 2019 state transport tenders. The regulator found no contravention by the company in its order passed on August 21. Stock closed at ₹3532.90 in the previous session, down 0.93%.
• Fund raise: Shareholders approved a ₹1,000 crore non-convertible debenture (NCD) issuance and a ₹35 per share dividend for FY26 at the 67th AGM. All six resolutions, including board reappointments, passed successfully.

Advait Energy Transitions

• Order Book: The company secured a ₹134.62 crore turnkey order from MPPTCL for an Emergency Restoration System. The contract aims to restore grid capacity quickly after line disruptions for the Madhya Pradesh state transmission utility. Stock closed at ₹2061.60 in the previous session, down 0.36%.
• Corporate action: The 16th AGM is scheduled for September 21 to approve FY26 financials, with a dividend record date set for September 14.

Transpek Industry

• Guidance: Co-Managing Director guided 15-20% revenue growth for FY27 despite a 42.7% YoY fall in Q1 PAT to ₹8.9 crore. The company plans ₹250 crore capex for a new Odisha manufacturing site to double business size in five years. Stock closed at ₹1335.00 in the previous session, down 2.70%.
• Earnings: FY26 net profit fell 6.35% to ₹456.5 crore on lower export sales, though domestic revenue grew 9.4%. EBITDA margin slipped to 16.5%, but finance costs decreased.

Cupid

• Management: Promoter Aditya Kumar Halwasiya acquired over 2.4 lakh shares in recent open-market transactions, raising his stake to 33.54%. The promoter group’s holding stands at 46.49%, signaling strong internal confidence. Stock closed at ₹281.76 in the previous session, down 1.62%.
• Guidance: The company guides for FY27 revenue of ₹725-750 crore and net profit of ₹210-225 crore, targeting ₹1,500 crore revenue by FY29.

Borosil

• Earnings: The company disclosed the availability of audio recordings for its Q4FY26 earnings call, complying with SEBI LODR Regulation 30. The recording covers unaudited standalone and consolidated results for the quarter ended June 30, 2026. Stock closed at ₹261.45 in the previous session, up 2.92%.

Vivid Electromech

• Order Book: Secured orders aggregating ₹52.81 crore for panel supply contracts, strengthening the company’s order book. Stock closed at ₹0 in the previous session, flat.

Arss Infrastructure Projects

• Order Book: Won a ₹104.06 crore order from East Coast Railway for road over bridge construction, adding to its railway infrastructure project portfolio. Stock closed at ₹0 in the previous session, flat.

B.R. Goyal Infrastructure

• Order Book: Secured a ₹151.06 crore order from NHAI for user fee collection at Jajau Fee Plaza in MP. The one-year agreement covers toll operations on a national highway. Stock closed at ₹0 in the previous session, flat.

Bottom Line

Regulatory clarity is driving sentiment for CEAT, while Cipla’s USFDA issues introduce caution for healthcare exporters. Infrastructure and specialty chemicals remain resilient with robust order inflows and clear growth guidance, keeping mid-cap momentum intact despite mixed earnings reactions.